A new biomarker in liver tumor may help doctors predict how patients respond to immunotherapy.
Group LeaderInstitute of Molecular and Cell Biology
Joe Yeong is a Group Leader at A*STAR’s Institute of Molecular and Cell Biology (IMCB). His main research focus is to understand and overcome the resistance of immune checkpoint blockade immunotherapy. He is the pioneer and in automation of quantitative multiplex immunohistochemistry, using clinical autostainers to study and quantitate tumor immune microenvironment in clinical samples. His works on cancer immunology are included in multiple National Medical Research Council-funded studies, as well as pharmaceutical industry-sponsored projects. Yeong served as a committee member in the World Immunotherapy Council, Society for Immunotherapy of Cancer (SITC) and is one of the organizers for its 2019 WIC Global Symposium in Washington DC, USA. He serves as a Secretary (Executive) for the Singapore Society of Oncology’s Cancer Immunotherapy Consortium.